TDP-43 Aggregation as a Feature of Vascular Dementia

Key Takeaways

• Chronic hypoperfusion drives TDP‑43 cytoplasmic mislocalisation.
• Phosphorylated TDP‑43 accumulates in cortex and hippocampus.
• Total TDP‑43 levels remain stable despite pathology.
• TDP‑43 changes mirror ALS and Alzheimer’s proteinopathies.
• Targeting TDP‑43 may mitigate vascular dementia progression.

Pulse Analysis

Vascular dementia (VaD) is the second most common cause of dementia worldwide, driven largely by chronic cerebral hypoperfusion (CCH) that reduces blood flow by up to 40 %. The resulting hypoxia triggers oxidative stress, mitochondrial dysfunction, and neuroinflammation, which together erode blood‑brain barrier integrity and promote white‑matter lesions. While clinicians have long focused on vascular risk factors, the molecular cascades that translate reduced perfusion into neuronal loss remain incompletely mapped. Recent work is beginning to bridge that gap by examining proteinopathies traditionally associated with primary neurodegeneration.

The TAR DNA‑binding protein 43 (TDP‑43) is a nuclear RNA‑binding protein essential for synaptic health and stress responses. In diseases such as ALS, frontotemporal dementia, and Alzheimer’s, TDP‑43 undergoes hyperphosphorylation, nuclear‑to‑cytoplasmic mislocalisation, and aggregation, forming toxic inclusions. The new study shows that CCH alone can provoke the same pathological modifications in mouse cortex and hippocampus, with phosphorylated TDP‑43 accumulating over time while total protein levels stay constant. This convergence suggests that vascular injury can hijack the same protein‑misfolding pathways that drive classic neurodegenerative disorders.

Recognising TDP‑43 as a mediator of VaD opens several translational opportunities. Phospho‑TDP‑43 could serve as a fluid or imaging biomarker to identify patients at risk of rapid cognitive decline, while small‑molecule inhibitors of TDP‑43 aggregation or kinase modulators might blunt downstream neuroinflammation. Moreover, the findings encourage cross‑disease collaborations, leveraging ALS and Alzheimer’s drug pipelines for vascular dementia trials. Future research will need to delineate whether TDP‑43 pathology is a cause or a by‑product of hypoperfusion, but the mechanistic link already reshapes how we view vascular contributions to dementia.